ranimustine
Small moleculeexperimental
Ranimustine is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT01173887)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O- Mol. weight
- 327.72 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRanimustine ↗
- ChEMBLCHEMBL2105348 ↗
Also known as
- alpha-d-glucopyranoside, methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-
- cymerin
- cymerine
- mcnu
- methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl) amino)-6-deoxy-alpha-d-glucopyranoside
- methyl 6-(3-(2-chloroethyl)-3-nitrosoiureido)-6-deoxy-alpha-d-glucopyranoside
- methyl 6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-alpha-d-glucopyranoside
- ranimustine
- ranimustine
- ranimustine
- ranimustine
- ranimustine
- ranimustine
- ranimustine
- ranimustine, (beta)-(d)-isomer
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01173887 | Phase 2 | Jul 1, 2010 | Kyowa Hakko Kirin |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyowa Hakko Kirin | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1